Valuation: ADMA Biologics, Inc.

Market Cap 2.04B 1.79B 1.66B 1.53B 2.87B 195B 2.92B 19.75B 7.73B 96.53B 7.65B 7.48B 333B P/E 2026 *
10.9x
P/E 2027 * 8.6x
Enterprise Value 2.04B 1.79B 1.66B 1.53B 2.87B 195B 2.92B 19.75B 7.73B 96.53B 7.65B 7.48B 333B EV / Sales 2026 *
3.81x
EV / Sales 2027 * 2.91x
Free-Float
93.48%
Yield 2026 *
-
Yield 2027 * -
1 day+3.66%
1 week+2.33%
Current month+5.02%
1 month+0.46%
3 months-19.36%
6 months-46.17%
Current year-51.81%
1 week 8.16
Extreme 8.165
8.8
1 month 8.16
Extreme 8.165
9.33
Current year 7.21
Extreme 7.2101
18.95
1 year 7.21
Extreme 7.2101
20.46
3 years 3.06
Extreme 3.06
25.67
5 years 1.01
Extreme 1.01
25.67
10 years 1.01
Extreme 1.01
25.67
Manager TitleAgeSince
Chief Executive Officer 49 2011-09-30
Director of Finance/CFO 49 2026-02-25
Compliance Officer 39 2017-12-31
Director TitleAgeSince
Director/Board Member 78 2006-12-31
Chairman 62 2012-03-29
Director/Board Member 49 2006-12-31
Date Insider Type Main position Quantity % Market Cap.
7/16/26 Free

Chief Financial Officer

221,493 0.0956%
5/27/26 Buy

Founder

6,400 0.0028%
5/12/26 Buy

Founder

12,500 0.0054%
Change 5-day change 1-year change 3-year change Capi.($)
+3.66%+2.33%-51.17%+118.11% 2.04B
+4.20%+2.96%+24.44%-6.82% 70.73B
+0.12%+2.96%+35.37%+211.10% 54.27B
+0.26%+54.90%+54.90%+54.90% 49.28B
+7.15%+8.59%-52.92%-52.31% 39.94B
+2.73%+1.21%+59.04%-22.48% 30.36B
+9.30%+10.68%+85.19%+105.94% 25.96B
+0.31%-6.46%+64.57%-52.97% 22.14B
-0.22%-2.76%-10.26%+159.25% 19.96B
+1.70%+3.76%+85.05%+148.55% 16.77B
Average +2.92%+2.60%+29.42%+66.33% 33.14B
Weighted average by Cap. +2.91%+3.36%+32.56%+55.50%

Financials

2026 *2027 *
Net sales 534M 469M 437M 402M 753M 51.05B 766M 5.18B 2.03B 25.32B 2.01B 1.96B 87.47B 701M 615M 573M 527M 987M 66.93B 1B 6.79B 2.66B 33.19B 2.63B 2.57B 115B
Net income 194M 170M 159M 146M 273M 18.54B 278M 1.88B 736M 9.19B 728M 713M 31.76B 250M 220M 205M 188M 353M 23.92B 359M 2.43B 950M 11.86B 940M 920M 40.99B
Net Debt - -
Logo ADMA Biologics, Inc.
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Employees
644
Date Price Change Volume
26-07-28 US$8.790 +3.66% 2,171,987
26-07-27 US$8.480 +2.54% 2,388,882
26-07-24 US$8.270 -1.19% 2,341,122
26-07-23 US$8.370 -0.12% 2,617,491
26-07-22 US$8.380 -2.44% 1,986,378
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.790USD
Average target price
17.00USD
Spread / Average Target
+93.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADMA Stock